Belli, Valentina
Matrone, Nunzia
Napolitano, Stefania
Migliardi, Giorgia
Cottino, Francesca
Bertotti, Andrea
Trusolino, Livio
Martinelli, Erika
Morgillo, Floriana
Ciardiello, Davide
De Falco, Vincenzo
Giunta, Emilio Francesco
Bracale, Umberto
Ciardiello, Fortunato
Troiani, Teresa
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (IG 18972)
Article History
Received: 6 March 2019
Accepted: 13 May 2019
First Online: 4 June 2019
Ethics approval and consent to participate
: The University of Campania “Luigi Vanvitelli” (Naples, Italy) and Candiolo Cancer Institute (Torino, Italy) approved this study.
: All authors agree on publication of the results of the present manuscript.
: TT: advisory board for Amgen, Bayer, Merck, Servier, Roche, Sanofi. EM: advisory board for Amgen, Bayer, Merck, Roche, Sanofi, Servier, Biocartis and expert opinion for ESMO (European Society of Medical Oncology).FM: advisory boards: MSD, Lilly; institutional research grants: AstraZeneca. FC: Advisory Boards, Bayer, Merck KgA, Roche, Servier, Amgen, Symphogen, Pfizer; Research funds, Roche, Bayer, Merck KgA, Ipsen, Amgen.LV: Symphogen, Merus, Pfizer, Servier, Eli Lilly, AstraZeneca, Merck. AB: Relay Therapeutics. VB, NM, SN, GM, FC, DC, VDF, EFG and UB declare no competing conflict of interest regarding the following manuscript.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.